Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

King Cuts Workforce By 20% In Wake Of Altace Decision

This article was originally published in The Pink Sheet Daily

Executive Summary

Size and focus of sales force will be restructured, King says.

You may also be interested in...



King Looks To Reign Over Pain With Acura Deal

Deal covers development and commercialization of four immediate-release opioid analgesics, including Acurox tablets for acute pain.

King Looks To Reign Over Pain With Acura Deal

Deal covers development and commercialization of four immediate-release opioid analgesics, including Acurox tablets for acute pain.

King/Palatin Put Phase III Plans For Erectile Dysfunction Product On Hold

Risk/benefit profile for bremelanotide unacceptable for first-line use, but compound may have value as second-line therapy for PDE-5 nonresponders, FDA says.

Topics

UsernamePublicRestriction

Register

LL1129367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel